Accession Number:

AD1093169

Title:

Therapeutic Strategies against Cyclin E1-Amplified Ovarian Cancers

Descriptive Note:

Technical Report,30 Sep 2015,29 Sep 2018

Corporate Author:

Wistar Institute Philadelphia United States

Personal Author(s):

Report Date:

2018-12-01

Pagination or Media Count:

25.0

Abstract:

For Aim 1, we demonstrated 1 The HSP90-inhibitors 17-AAG and AT13387 has single agent activity against CCNE1-amplifiedcell lines 2 HSP90-inhibition downregulates homologous recombination HR DNA repair and downregulates expression of HR pathway genes 3 The HSP90-inhibitor AT13387 synergizes with platinum against CCNE1-amplified cell lines. For Aim 2, we demonstrated 1 FOXM1 is necessary for the survival of CCNE1 amplified epithelial ovarian cancer cells.2 FOXM1 interacts with Rb in CCNE1 amplified epithelial ovarian cancer cells. 3Characterized small molecule inhibitor that disrupts the interaction between FOXM1 and Rb in CCNE1 amplified epithelial ovarian cancer cells. For Aim 3, we demonstrated 1 Certain miRNAs including miR-1255b, miR-148b, and miR-193b inhibit HR DNA repair 2 These miRNAs synergize with platinum against CCNE1-amplified cell lines, that is expression of these miRNAs sensitizes cells to platinum.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE